NewEdge Advisors LLC Has $93.22 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

NewEdge Advisors LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 1.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 120,747 shares of the company’s stock after selling 1,335 shares during the quarter. Eli Lilly and Company accounts for about 0.6% of NewEdge Advisors LLC’s holdings, making the stock its 26th largest position. NewEdge Advisors LLC’s holdings in Eli Lilly and Company were worth $93,217,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Highline Wealth Partners LLC raised its stake in Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after acquiring an additional 20 shares in the last quarter. FPC Investment Advisory Inc. lifted its holdings in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $48,000. Compass Financial Services Inc bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $58,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a report on Thursday, January 16th. Guggenheim dropped their target price on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a research note on Monday. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Morgan Stanley lowered their price target on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. Finally, Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,012.00.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.3 %

LLY opened at $756.55 on Wednesday. The company has a market cap of $717.34 billion, a P/E ratio of 64.61, a PEG ratio of 1.40 and a beta of 0.51. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company’s 50 day moving average is $832.96 and its 200-day moving average is $821.54. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.